Release Summary

Cellectis Patent Encompassing Broad Uses of Gene Editing Technologies Maintained by USPTO U.S. Patent 8,921,332 Refers to the Use of Chimeric Endonucleases, such as ZFN, TALEN Mega-TALs & CRISPR-Cas9

Cellectis